Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization
Authors:
Open Access
- 20 August 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0202269
Abstract
Zoledronic acid (ZA) exerts complex influence on bone by suppressing bone resorption, mostly due to the direct osteoclasts inhibition and uncertain influence on osteoblasts. Vitamin K2 (VK2, Menaquinone-4) as an anabolic agent stimulates bone formation via anti-apoptosis in osteoblasts and mild osteoclasts inhibition. Based on these knowledge, the therapeutic effect of the combined or sequential therapy of VK2 and ZA depends on the influence on the osteoblasts, since both cases exert similar inhibitory effect on osteoclasts. In a series of in vitro studies, we confirmed the protective effect of VK2 in osteoblasts culture, especially when followed by exposure to ZA, and the proliferation and mineralization inhibition induced by ZA towards osteoblasts. For mechanism study, expression of bcl-2/bax, Runx2 and Sost in cells were examined. For in vivo studies, an osteoporosis animal model was established in rats via ovariectomy (OVX) and subjected to sequential treatment, namely VK2 followed by ZA. Bone mineral density (BMD) was measured by Dual energy X-ray absorptionmetry (DEXA), morphology and mechanical parameters by micro-computed tomography (micro-CT), mechanical strength by an electro-hydraulic fatigue-testing machine. The bone calcium, hydroxyproline content, blood lipids were evaluated using microplate technique, and the bone surface turnover was evaluated using the fluorescence in corporation method. It was found that VK2 pretreatment partially prevented the inhibition of bone formation caused by ZA, which was reflected by indices like BMD, bone calcium content and bone strength. The underling mechanisms for protection of VK2 pretreatment, mainly demonstrated via in vitro studies, included inhibiting apoptosis and depressing Sost expression in osteoblasts, which in turn improved the osteoporosis therapeutic effects of ZA. These findings suggested that pretreatment with VK2 before ZA therapy might serve a new long-term therapy protocol for osteoporosis.Keywords
This publication has 35 references indexed in Scilit:
- Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosisJournal of Bone and Mineral Metabolism, 2016
- Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defectBone, 2016
- Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cellsOncotarget, 2015
- Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in ratsBMC Musculoskeletal Disorders, 2012
- [Combination therapy for osteoporosis].2009
- Bone turnover 18 months after a single intravenous dose of zoledronic acidInternational Journal Of Clinical Practice, 2007
- New anabolic therapies in osteoporosisEndocrinology and Metabolism Clinics of North America, 2003
- Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivoJournal of Bone and Mineral Research, 1995
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Journal of Clinical Investigation, 1991
- A new direction for osteoporosis research: A review and proposalBone, 1991